1,065 research outputs found

    Effects of Heat-Producing Elements on the Stability of Deep Mantle Thermochemical Piles

    Get PDF
    ©2020. American Geophysical Union. All Rights Reserved. Geochemical observations of ocean island and mid-ocean ridge basalts suggest that abundances of heat-producing elements (HPEs: U, Th, and K) vary within the mantle. Combined with bulk silicate Earth models and constraints on the Earth's heat budget, these observations suggest the presence of a more enriched (potentially deep and undepleted) reservoir in the mantle. Such a reservoir may be related to seismically observed deep mantle structures known as large low shear velocity provinces (LLSVPs). LLSVPs might represent thermochemical piles of an intrinsically denser composition, and many studies have shown such piles to remain stable over hundreds of Myr or longer. However, few studies have examined if thermochemical piles can remain stable if they are enriched in HPEs, a necessary condition for them to constitute an enriched HPE reservoir. We conduct a suite of mantle convection simulations to examine the effect of HPE enrichment up to 25× the ambient mantle on pile stability. Model results are evaluated against present-day pile morphology and tested for resulting seismic signatures using self-consistent potential pile compositions. We find that stable piles can form from an initial basal layer of dense material even if the layer is enriched in HPEs, depending on the density of the layer and degree of HPE enrichment, with denser basal layers requiring increased HPE enrichment to form pile-like morphology instead of a stable layer. Thermochemical piles or LLSVPs may therefore constitute an enriched reservoir in the deep mantle

    8th International Conference: Primary Therapy of Early Breast Cancer, St Gallen, Switzerland, March 12–15 2003

    Get PDF
    The International St Gallen Breast Cancer Conference concentrates almost exclusively on adjuvant, multimodal primary therapy for early breast cancer. Begun 25 years ago, this meeting was initially held every 4 years, but therapeutic progress, new strategies and provocative trials data have accelerated to the extent that conferences are now held biennially. The meeting this year was attended by almost 3000 delegates. Major topics included new prognostic and predictive markers in early breast cancer, the best use of adjuvant chemotherapy and endocrine therapy, and innovations in local surgery and radiation therapy

    Report on the 4th European Breast Cancer Conference, Hamburg, Germany, 16–20 March 2004

    Get PDF
    The 4th European Breast Cancer Conference, organized under the auspices of the European Organization for Research and Treatment of Cancer Breast Cancer Group, of the European Breast Cancer Coalition (Europa Donna) and of the European Society of Mastology (EUSOMA), was held in Hamburg, Germany on 16–20 March 2004. The leading theme of the conference was partnership among scientists, clinicians, carers, advocates and patients. The present article provides a brief description of the most important conference presentations on molecular biology, epidemiology, prevention, pathology, diagnosis and treatment at all stages of breast cancer

    Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics

    Get PDF
    β-site APP cleaving enzyme 1 (BACE1) is a transmembrane aspartyl protease with a lumenal active site that sheds the ectodomains of membrane proteins through juxtamembrane proteolysis. BACE1 has been studied principally for its role in Alzheimer's disease as the β-secretase responsible for generating the amyloid-β protein. Emerging evidence from mouse models has identified the importance of BACE1 in myelination and cognitive performance. However, the substrates that BACE1 processes to regulate these functions are unknown, and to date only a few β-secretase substrates have been identified through candidate-based studies. Using an unbiased approach to substrate identification, we performed quantitative proteomic analysis of two human epithelial cell lines stably expressing BACE1 and identified 68 putative β-secretase substrates, a number of which we validated in a cell culture system. The vast majority were of type I transmembrane topology, although one was type II and three were GPI-linked proteins. Intriguingly, a preponderance of these proteins are involved in contact-dependent intercellular communication or serve as receptors and have recognized roles in the nervous system and other organs. No consistent sequence motif predicting BACE1 cleavage was identified in substrates versus non-substrates. These findings expand our understanding of the proteins and cellular processes that BACE1 may regulate, and suggest possible mechanisms of toxicity arising from chronic BACE1 inhibition

    A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer

    Get PDF
    Accelerated (dose-dense) chemotherapy, in which the frequency of administration is increased without changing total dose or duration, may increase the efficacy of cancer chemotherapy. We performed a randomised Phase II study to assess the safety and relative toxicity of AC (doxorubicin; cyclophosphamide) vs E(epirubicin)C given by conventional or accelerated schedules as neoadjuvant or adjuvant chemotherapy for early breast cancer. Furthermore, the relative toxicity of doxorubicin and epirubicin remains uncertain. Patients were randomised to one of four arms; four courses of standard 3 weekly cyclophosphamide 600 mg m−2 in combination with doxorubicin 60 mg m−2 (AC) vs epirubicin 90 mg m−2 (EC) 3 weekly vs the same regimens administered every 2 weeks with pegfilgrastim (G-CSF). A total of 126 patients were treated, 42 with standard AC, 42 with accelerated AC, 19 with standard EC and 23 with accelerated EC. Significantly more grade 3/4 day one neutropenia was seen with standard (6/61, 10%) compared to accelerated (0/65,) regimens (P=0.01). A trend towards more neutropenic sepsis was seen in the combined standard and accelerated AC arms (12/84, 14%) compared to the combined EC arms (1/42, 2%), P=0.06. Falls in left ventricular ejection fraction were not increased with accelerated treatment. Accelerated AC and EC with pegfilgrastim are safe and feasible regimens in the treatment of early breast cancer with less neutropenia than conventional 3 weekly schedules
    • …
    corecore